Immunology and inflammation | pharmaphorum

Friday 5 December 2025

Immunology and inflammation

News

Merck fires up a $10.8bn Prometheus takeover bid

Merck fires up a $10.8bn Prometheus takeover bid

Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion.

News

Acelyrin's Shao-Lee Lin

Acelyrin files IPO – is a biotech comeback on the way?

Initial public offerings in the biotech sector nosedived last year after a lot of activity in 2021, but have remained few and far between this year amid tough economic con

News

BenevolentAI lead atopic dermatitis drug misses the mark

BenevolentAI lead atopic dermatitis drug misses the mark

BenevolentAI has reported disappointing results in a phase 2 trial of lead drug BEN-2293 in atopic dermatitis (AD), as the drug was unable to show the hoped-for effect on

News

Gilead presses go on first Nurix protein degrader drug

Gilead presses go on first Nurix protein degrader drug

Opt-in for IRAK4 drug comes after a Kymera/Sanofi candidate showed early activity in trials.

News

Chasing BMS, Takeda trumpets TYK2 data in psoriasis

Chasing BMS, Takeda trumpets TYK2 data in psoriasis

Pharma group is hoping for big things, after splashing out $4bn upfront for the drug last year.

News

$AbbVie’s Skyrizi hits the spot in refractory psoriasis$

AbbVie’s Skyrizi hits the spot in refractory psoriasis

Antibody works when IL-17 inhibitors Like Novartis' Cosentyx and Lilly's Taltz fail.